TABLE 1.

Baseline patient, tumor and molecular characteristics of non-small-cell lung cancers with or without anaplastic lymphoma kinase (ALK) kinase domain splicing variants

	Total (n=270)
	ALK kinase domain splicing variant expression (n=30)	Lack of ALK kinase domain splicing variant expression (n=240)	p-value
Age median(range)	61 (29-81)	64 (33-79)	0.110
Women n (%)	13 (43.3%)	123 (51.2%)	0.444
Race n (%)  Asian  White	29 (96.7%) 1 (3.3%)	239 (99.6%) 1 (0.4%)	0.210
Smoking status n (%)  Current smoker  Former smoker  Never smoker	12 (40.0%) 4 (13.3%) 14 (46.7%)	77 (32.1%) 33 (13.8%) 130 (54.1%)	0.660
Stage n (%)  I  II  III  IV	16 (53.3%) 2 (6.7%) 9 (30.0%) 3 (10.0%)	138 (57.5%) 45 (18.8%) 52 (21.7%) 5 (2.1%)	0.033
Histology n (%)  Adenocarcinoma  Squamous cell carcinoma  Other (NOS)	24 (80.0%) 4 (13.3%) 2 (6.7%)	189 (78.8%) 30 (12.5%) 21 (8.7%)	0.925
EGFR mutation n (%)   Positive/Mutated   Negative/Wild-type	9 (30%) 21 (70%)	116 (48.3%) 124 (51.7%)	0.079
KRAS mutation n (%)   Positive/Mutated   Negative/Wild-type	3 (10%) 27 (90%)	19 (7.9%) 221 (92.1%)	0.721
ALK rearrangement n (%)   Positive   Negative	4 (13.3%) 26 (86.6%)	15 (6.2%) 225 (93.8%)	0.244
ALK splicing variant n (%)   exon 23 skipping   exon 27 skipping	19 (63.3%) 11 (36.7%)	0 (0%) 0 (0%)	NA

n, number; EGFR, epidermal growth factor receptor; KRAS, v-ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NOS, not otherwise specified